Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 5 mg Linagliptin (Tradjenta) Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

NCT02372630
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

NCT01778049
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, BI 10773 Placebo, BI 10773 / BI 1356, BI 10773 / BI 1356 Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Chino, California • Huntington Beach, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

NCT01897532
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
197
States / cities
Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

NCT00328172
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily, Metformin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
21 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
34
States / cities
Chula Vista, California • La Jolla, California • Walnut Creek, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

NCT03281369
View directory record Official record
Conditions
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Interventions
5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

NCT01342484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, BI1356 low dose, BI1356 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Antonio, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin as Add on to Basal Insulin in the Elderly

NCT02240680
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
60 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
38
States / cities
Sheffield, Alabama • Chula Vista, California • Costa Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

NCT01845077
View directory record Official record
Conditions
Healthy
Interventions
2x500 mg Metformin (Glumetza), 5 mg Linagliptin/1000 mg Metformin FDC, 5 mg Linagliptin (Tradjenta), 3x500 mg Metformin (Glumetza), 2 x 500 mg Metformin (Glumetza), 5 mg Linagliptin/1000mg Metformin FDC, 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 4 Interventional

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

NCT02442817
View directory record Official record
Conditions
Schizophrenia
Interventions
Linagliptin
Drug
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

NCT00601250
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • Spring Valley, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

NCT01087502
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
16
States / cities
Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

NCT00996658
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 79 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
29
States / cities
Escondido, California • Greenbrae, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

NCT01512979
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
metformin, linagliptin, metformin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Chino, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

NCT00736099
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 82 Years
Enrollment
2,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Chula Vista, California • Spring Valley, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

NCT01734785
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 27, 2026, 4:51 AM EDT
Withdrawn Phase 4 Interventional

Effects of DPP4 Inhibition on COVID-19

NCT04341935
View directory record Official record
Conditions
Coronavirus Infection, Type 2 Diabetes
Interventions
Linagliptin, Insulin regimen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

NCT00800683
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
24
States / cities
Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

NCT00819091
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • National City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

NCT00954447
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
47
States / cities
Escondido, California • Fresno, California • Greenbrae, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

NCT01792518
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin 5mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • North Hollywood, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 27, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

NCT03429543
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 27, 2026, 4:51 AM EDT